Literature DB >> 31401124

Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project.

Andrea Gaedigk1, Amy Turner2, Robin E Everts3, Stuart A Scott4, Praful Aggarwal2, Ulrich Broeckel2, Gwendolyn A McMillin5, Roberta Melis6, Erin C Boone1, Victoria M Pratt7, Lisa V Kalman8.   

Abstract

Pharmacogenetic testing increasingly is available from clinical and research laboratories. However, only a limited number of quality control and other reference materials currently are available for the complex rearrangements and rare variants that occur in the CYP2D6 gene. To address this need, the Division of Laboratory Systems, CDC-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing and research communities and the Coriell Cell Repositories (Camden, NJ), has characterized 179 DNA samples derived from Coriell cell lines. Testing included the recharacterization of 137 genomic DNAs that were genotyped in previous Genetic Testing Reference Material Coordination Program studies and 42 additional samples that had not been characterized previously. DNA samples were distributed to volunteer testing laboratories for genotyping using a variety of commercially available and laboratory-developed tests. These publicly available samples will support the quality-assurance and quality-control programs of clinical laboratories performing CYP2D6 testing.
Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31401124      PMCID: PMC6854474          DOI: 10.1016/j.jmoldx.2019.06.007

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  17 in total

1.  The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity.

Authors:  Jean C Dinh; Erin C Boone; Vincent S Staggs; Robin E Pearce; Wendy Y Wang; Roger Gaedigk; James Steven Leeder; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-11-30       Impact factor: 6.875

2.  Characterization of Reference Materials for TPMT and NUDT15: A GeT-RM Collaborative Project.

Authors:  Victoria M Pratt; Wendy Y Wang; Erin C Boone; Ulrich Broeckel; Neal Cody; Lisa Edelmann; Andrea Gaedigk; Ty C Lynnes; Elizabeth B Medeiros; Ann M Moyer; Matthew W Mitchell; Stuart A Scott; Petr Starostik; Amy Turner; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2022-08-02       Impact factor: 5.341

Review 3.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

4.  PharmVar and the Landscape of Pharmacogenetic Resources.

Authors:  Andrea Gaedigk; Michelle Whirl-Carrillo; Victoria M Pratt; Neil A Miller; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-11-23       Impact factor: 6.875

5.  Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization.

Authors:  Amy J Turner; Praful Aggarwal; Erin C Boone; Cyrine-Eliana Haidar; Mary V Relling; Ashley D Derezinski; Ulrich Broeckel; Andrea Gaedigk
Journal:  J Mol Diagn       Date:  2021-02-22       Impact factor: 5.568

Review 6.  Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Andrea Gaedigk; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; R H N van Schaik; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2021-06-10       Impact factor: 5.341

7.  Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project.

Authors:  Victoria M Pratt; Amy Turner; Ulrich Broeckel; D Brian Dawson; Andrea Gaedigk; Ty C Lynnes; Elizabeth B Medeiros; Ann M Moyer; Deborah Requesens; Francesco Vetrini; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2021-05-19       Impact factor: 5.341

8.  Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes.

Authors:  Yaowaluck Hongkaew; Wendy Y Wang; Roger Gaedigk; Chonlaphat Sukasem; Andrea Gaedigk
Journal:  Pharmacogenomics       Date:  2021-05-17       Impact factor: 2.638

9.  A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: a focus on CYP2D6 genotyping.

Authors:  David Twesigomwe; Galen E B Wright; Britt I Drögemöller; Jorge da Rocha; Zané Lombard; Scott Hazelhurst
Journal:  NPJ Genom Med       Date:  2020-08-03       Impact factor: 8.617

10.  Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.

Authors:  Sylvan M Caspar; Timo Schneider; Janine Meienberg; Gabor Matyas
Journal:  Int J Mol Sci       Date:  2020-03-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.